Zhejiang Huahai Pharmaceutical Co., Ltd.

Zhejiang Huahai Pharmaceutical Co., Ltd. saw a significant intraday gain, contrasting with its recent longer-term declines. Over the past year, the company has underperformed the market, with key financial metrics indicating challenges, including a relatively high valuation and modest return on equity. Its market capitalization stands at CNY 22,852 million.

Zhejiang Huahai Pharmaceutical Co., Ltd. faced a notable decline in its stock today, contrasting with broader market trends. The company has struggled over the past week and month, with significant annual and year-to-date losses. Financial metrics indicate high debt levels and low return on equity, raising concerns about its stability.

Zhejiang Huahai Pharmaceutical Co., Ltd. faced a significant stock decline, reflecting ongoing performance challenges. The company reported a decrease in net sales and operating profit, alongside a high debt-to-equity ratio. Its financial indicators suggest a difficult market environment, despite a modest dividend yield.

Zhejiang Huahai Pharmaceutical Co., Ltd. saw a significant intraday increase on March 6, 2026, contrasting with the modest gain of the China Shanghai Composite. However, the company's long-term performance reveals challenges, including a decline in net sales and negative operating profit growth, despite its large market capitalization.

Zhejiang Huahai Pharmaceutical Co., Ltd. faced a decline in stock value, reflecting ongoing challenges. The company has experienced significant long-term hurdles, including a high debt-to-equity ratio and decreasing net sales and operating profit. These factors contribute to its underperformance relative to broader market trends.